All In Biotech

Drug Trial Radar · NCT01358240

Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis

A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-Blinded Comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects With Interdigital Tinea Pedis

Last checked: Nov 19, 2026Latest source record: Sep 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

336

Actual

Start

Jun 2011

Primary completion

Apr 2012

Study completion Aug 2012

Sponsor

Lead sponsor
AmDermaIndustry
Sponsor type
Industry
Collaborators
AmDerma Pharmaceuticals, LLC
First posted
May 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of the safety and efficacy of Econazole Nitrate Foam 1% and the Foam Vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes). This is a 6 week study which has a 4 week treatment period and a 2 week follow-up evaluation. The study will also utilize Econazole Nitrate Cream 1% (for safety comparison) and a Placebo cream for blinding purposes only.

Conditions

  • Tinea Pedis
  • Athlete's Foot

Interventions

  • Econazole Nitrate Foam 1%Drug

    Econazole Nitrate Foam 1% applied once a day for 4 weeks

  • Vehicle FoamDrug

    Vehicle Foam applied once a day for 4 week

  • Econazole Nitrate Cream 1%Drug

    Econazole Nitrate Foam 1% applied once a day for 4 weeks

  • Placebo CreamOther

    Placebo cream applied once a day for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete CureTime frame: Day 43

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Sunil S. Dhawan, MD

    Fremont, California

  • Guy F. Webster, MD, PhD

    Hockessin, Delaware

  • Marta I. Rendon, MD

    Boca Raton, Florida

  • Jonathan Kantor, MD

    Jacksonville, Florida

  • Steven E. Kempers, MD

    Fridley, Minnesota

  • Joel Schlessinger, MD

    Omaha, Nebraska

  • Phoebe Rich, MD

    Portland, Oregon

  • Edward J. Primka III, MD

    Knoxville, Tennessee

  • Michael T. Jarratt, MD

    Austin, Texas

  • William Abramovits, MD

    Dallas, Texas

  • David M. Pariser, MD, FAAD, FACP

    Norfolk, Virginia

  • Harry H. Sharata, MD, PhD

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.